<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818829</url>
  </required_header>
  <id_info>
    <org_study_id>13 038 07</org_study_id>
    <nct_id>NCT02818829</nct_id>
  </id_info>
  <brief_title>Biological and Clinical Database for Pancreatic Adenocarcinoma</brief_title>
  <acronym>BACAP</acronym>
  <official_title>Biological and Clinical Database for Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACAP is a biobank dedicated to the pancreatic adenocarcinoma funded by institut national
      institue du cancer (INCa) and coordinated by Dr Barbara Bournet from Toulouse hospital. This
      base includes clinical data and biological samples such as blood, serum, plasma, saliva, DNA
      and RNA from tumors cells.

      The mission of this prospective project is to make available to the scientific community a
      clinical biological base from patients with pancreatic adenocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer represents the fifth cause of death by cancer in Western countries. In over
      90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic
      cancer remains the surgical exeresis. This one can only be suggested as a curative treatment
      in only 10 to 15% of cases. Besides, prevention or screening is impossible due to the absence
      of clearly identified risk factors or groups and to the absence of useful markers for the
      diagnosis in clinical practice.

      The research efforts in this area must face a double challenge: saving time while improving
      the diagnosis period and strengthen the therapeutic equipment. It is important to identify
      and characterise the new molecular markers applicable for a better diagnosis and/or treatment
      (especially the response factors to chemotherapy). The present project aims at creating a
      multicentre national network used to set up a clinical biological base (CBB) dedicated to the
      pancreatic adenocarcinoma, built on the best quality standards, for the biological resources
      as well as the associated clinical and epidemiological data.

      The originality of this CBB relies on the fact that it will have not only tumour tissues
      sampled from surgical specimens of resectable tumours but also cell and biopsy material from
      unresectable and/or metastatic tumours sampled under endoscopic ultrasonography (1500
      biopsies over 3 years coupled to systematic blood samples). Endoscopic ultrasonography is a
      technique used to specifically perform biopsies on pancreatic tumours and to obtain useful
      cell material for research. To these samples will be associated every clinical and
      epidemiological target data required for research projects related to this unique CBB in
      France. From these samples, DNA and RNA will be especially isolated, as it is a precious
      biological material for the programmed molecular analyses.

      There are many stakes: creating a French network in order to form, with the prospective plans
      over 3 years, a collection of tissue, biopsies, nucleic acids from pancreatic cancer
      associated to circulating blood samples and relevant clinical data. Thanks to this
      collection, the investigator team hope to be able to identify new molecular markers (from
      cancer tissue and/or circulating blood from pancreatic cancer patients) applicable to
      clinical practice to diagnose, to assess the prognosis or to predict the response to
      pancreatic cancer chemotherapy. The investigator team will also try to identify new risk
      factors for this cancer, especially regarding the diet. The base will thus be made up from 12
      different French centres from University Hospital and private Centres where
      gastroenterologists, oncologists, digestive surgeons, anatomopathologists, epidemiologists
      intervene as they are all associated to scientific teams dedicated to pancreatic cancer,
      itself already formed in collaborative networks.

      Investigators hope through this project: to get a unique and exceptional CBB for pancreatic
      cancer, to reach the required standards (especially Inca) for this CBB, and to be
      internationally recognised. This base will be a strong guarantee to identify new molecular
      markers for the diagnosis, the prognosis, and the predictive response to chemotherapy for
      pancreatic cancer, especially when locally advanced. Finally, the epidemiological projects
      related to this project are originally about the nutritional issues (regardless of the lipid
      diet and the cachexia) associated to pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Constitution of a transdisciplinary biobank with collection of biological samples with DNA</measure>
    <time_frame>Through the study completion, an average of 11 months</time_frame>
    <description>The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Constitution of a transdisciplinary biobank with collection of biological samples without DNA</measure>
    <time_frame>Through the study completion, an average of 11 months</time_frame>
    <description>The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <description>Collection of biological samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of biological samples</intervention_name>
    <description>Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsie,
      tissue from tumor and adjacent tissue of pancreas
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a pancreatic adenocarcinoma proven cytologically or histologically without
        any treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient eighteen years old

          -  Histologically or cytologically confirmed pancreatic adenocarcinoma

          -  Solid pancreatic mass explored with tomodensitometry or endoscopic ultrasonography
             fine-needle aspiration

          -  Informed consent signed

        Exclusion Criteria:

          -  no informed consent

          -  pregnancy women

          -  no histologically or cytologically confirmed pancreatic adenocarcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara BOURNET, MD; PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara BOURNET, MD; PHD</last_name>
    <phone>5 61 32 32 35</phone>
    <phone_ext>+33</phone_ext>
    <email>bournet.b@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy CANIVET, PHD</last_name>
    <phone>5 61 32 20 48</phone>
    <phone_ext>+33</phone_ext>
    <email>canivet.c@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VÃ©ronique VENDRELY., MD</last_name>
      <email>veronique.vendrely@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaujon Hospital</name>
      <address>
        <city>Clichy La Garenne</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal HAMMEL, MD; PHD</last_name>
      <email>pascal.hammel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>StÃ©phanie TRUANT, MD; PHD</last_name>
      <email>Stephanie.TRUANT@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume PIESSEN, MD; PHD</last_name>
      <email>Guillaume.PIESSEN@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre LÃ©on BÃ©rard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre GUIBERT, MD</last_name>
      <email>Pierre.GUIBERT@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Hospital Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand NAPOLEON</last_name>
      <email>bertrand.napoleon@dartybox.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-FranÃ§ois SEITZ, MD; PHD</last_name>
      <email>Jean-francois.SEITZ@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>StÃ©phane GARCIA</last_name>
      <email>Stephane.GARCIA@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FrÃ©deric BIBEAU, MD; PHD</last_name>
      <email>Frederic.Bibeau@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric ASSENAT, MD, PHD</last_name>
      <email>e-assenat@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of NICE</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffroy VANBIERVLIET, MD; PHD</last_name>
      <email>vanbiervliet.g@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique FARGE-BANCEL, MD, PHD</last_name>
      <email>dominique.farge-bancel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Trocadero</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent PALAZZO, MD</last_name>
      <email>laurent.palazzo@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pau Hospital</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BERTHELEMY, MD</last_name>
      <email>philippe.berthelemy@ch-pau.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis BUSCAIL, MD; PHD</last_name>
      <email>buscail.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves SCOAZEC, MD; PHD</last_name>
      <email>Jean-yves.SCOAZEC@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.chu-toulouse.fr/-projet-bacap-</url>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Endoscopic ultrasonography</keyword>
  <keyword>Fine-needle aspiration</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>DNA tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

